{"id":"generic-warfarin-2","safety":{"commonSideEffects":[{"rate":"1-3% major bleeding annually","effect":"Bleeding (major and minor)"},{"rate":"<1%","effect":"Warfarin-induced skin necrosis"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Alopecia"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1464","moleculeType":"Small molecule","molecularWeight":"308.33"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Warfarin is a coumarin anticoagulant that acts as a vitamin K antagonist. It inhibits the enzyme vitamin K epoxide reductase, which is essential for the carboxylation and activation of vitamin K-dependent clotting factors. This results in decreased synthesis of functional factors II, VII, IX, and X, prolonging the prothrombin time and reducing the risk of thromboembolism.","oneSentence":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:47:01.172Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention"},{"name":"Mechanical heart valve thromboprophylaxis"},{"name":"Post-myocardial infarction thromboprophylaxis"}]},"trialDetails":[{"nctId":"NCT04709094","phase":"PHASE1","title":"A Drug Interaction Study of Danicopan","status":"COMPLETED","sponsor":"Alexion Pharmaceuticals, Inc.","startDate":"2019-07-28","conditions":"Healthy","enrollment":52},{"nctId":"NCT02017197","phase":"PHASE4","title":"Therapeutic Equivalence Between Branded and Generic WARFArin Tablets in Brazil","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2014-08","conditions":"Atrial Fibrillation","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"generic warfarin #2","genericName":"generic warfarin #2","companyName":"Federal University of São Paulo","companyId":"federal-university-of-s-o-paulo","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Warfarin inhibits vitamin K-dependent clotting factors (II, VII, IX, X) by antagonizing vitamin K epoxide reductase, thereby reducing thrombin generation and preventing blood clot formation. Used for Atrial fibrillation for stroke prevention, Venous thromboembolism (deep vein thrombosis and pulmonary embolism) treatment and prevention, Mechanical heart valve thromboprophylaxis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}